Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML3OYH)

• Drug Name: TriMixDC Drug Info
• Synonyms: Dendritic cell vaccine (melanoma), Vrije Universiteit Brussel; TriMixDC (melanoma, intrademal), Universite Libre de Bruxelles

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DML3OYH

Molecule-Related Drug Atlas

Drug(s) Targeting TNF related activation protein (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[2]
BI 655064	DMF86P2	Lupus	4A40	Phase 2	[3]
Lucatumumab	DMY2L7V	Lymphoma	2A80-2A86	Phase 2	[4]
Dapirolizumab pegol	DMIYFWA	Systemic lupus erythematosus	4A40.0	Phase 2	[5]
PG-102	DMF5YEN	Autoimmune diabetes	5A10	Phase 2	[6]
ISF35	DMBZK3P	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[7]
CDP-7657	DMN8I5Q	Systemic lupus erythematosus	4A40.0	Phase 1	[8]
MEDI4920	DME7BMT	Rheumatoid arthritis	FA20	Phase 1	[9]
UltraCD40L	DMHG7DZ	Systemic lupus erythematosus	4A40.0	Phase 1	[10]
BPX-101	DM51MSD	Prostate cancer	2C82.0	Phase 1	[11]

Drug(s) Targeting CD70 antigen (CD27-L)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-74494550	DM3ICO6	Myelodysplastic syndrome	2A37	Phase 2	[12]
4SCAR19 and 4SCAR70	DMKC8F9	B-cell lymphoma	2A86	Phase 1/2	[13]
MDX-1203	DM0RIQF	Solid tumour/cancer	2A00-2F9Z	Phase 1	[14]
MDX-1411	DM3402P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[15]
BMS-936561	DMYIBFM	Haematological malignancy	2B33.Y	Phase 1	[16]
SGN-70	DMXA7W9	Autoimmune diabetes	5A10	Phase 1	[17]
SGN-CD70A	DMMJ1PO	Non-hodgkin lymphoma	2B33.5	Phase 1	[18]
Anti-hCD70 CAR transduced PBL	DMK4GIS	Ovarian cancer	2C73	Phase 1	[19]
AMG 172	DMS72GN	Renal cell carcinoma	2C90	Phase 1	[20]
SEA-CD70	DMX94YF	Acute myeloid leukaemia	2A60	Phase 1	[21]

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[22]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[23]
Resatorvid	DMFMWYC	Sepsis	1G40-1G41	Phase 3	[24]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[25]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[26]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[27]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[28]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[28]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD70 antigen (CD27-L)	TTNCIE0	CD70_HUMAN	Not Available	[1]
TNF related activation protein (CD40LG)	TTIJP3Q	CD40L_HUMAN	Not Available	[1]
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Not Available	[1]

References

• [1] Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int. 2013;2013:976383.
• [2] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [3] FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
• [4] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
• [7] Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
• [8] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
• [9] ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
• [10] CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
• [11] Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
• [12] Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents. Nat Med. 2020 Sep;26(9):1459-1467.
• [13] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [14] J Clin Oncol 32:5s, 2014 (suppl; abstr 2558).
• [15] Bristol-Myers Squibb swallows last of antibody pioneers. Nat Biotechnol. 2009 Sep;27(9):781-3.
• [16] Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacok... Biopharm Drug Dispos. 2016 Mar;37(2):93-106.
• [17] 2011 Pipeline of Seattle Genetics.
• [18] SGN-CD70A, a novel and highly potent anti-CD70 ADC, induces double-strand DNA breaks and is active in models of MDR+ renal cell carcinoma (RCC) and non-Hodgkin lymphoma (NHL). Cancer Research 10/2014; 74(19 Supplement):2647-2647.
• [19] ClinicalTrials.gov (NCT02830724) Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
• [20] National Cancer Institute Drug Dictionary (drug id 721679).
• [21] Clinical pipeline report, company report or official report of Seagen.
• [22] Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
• [23] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [24] Clinical pipeline report, company report or official report of Takeda (2009).
• [25] Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
• [26] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [27] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [28] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [29] Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013